title: Eltrombopag named patient programme for patients with chronic immune thrombocytopenia.
authors.forename: Maria
authors.initials: M
authors.lastname: Scully
authors.forename: Richard
authors.initials: R
authors.lastname: Kaczmarski
authors.forename: Bethan
authors.initials: B
authors.lastname: Myers
authors.forename: Rod
authors.initials: R
authors.lastname: Collins
authors.forename: Osa
authors.initials: O
authors.lastname: Emohare
authors.forename: Paula H B
authors.initials: PH
authors.lastname: Bolton-Maggs
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001565:Benzoates / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy* / Q000276:immunology; D011720:Pyrazoles / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D001565:Benzoates; D006834:Hydrazines; D011720:Pyrazoles; C520809:eltrombopag